Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 96, Issue 6, Pages 672-683Publisher
WILEY
DOI: 10.1038/clpt.2014.174
Keywords
-
Categories
Funding
- National Institutes of Health [DA-08924, NS-048295, AG-35844, HL-101186, AG-0001751, AG-042637]
- Research Program in Mitochondrial Therapeutics at the Weill Cornell Medical College
Ask authors/readers for more resources
The mitochondrial electron transport chain (ETC) plays a central role in energy generation in the cell. Mitochondrial dysfunctions diminish adenosine triphosphate (ATP) production and result in insufficient energy to maintain cell function. As energy output declines, the most energetic tissues are preferentially affected. To satisfy cellular energy demands, the mitochondrial ETC needs to be able to elevate its capacity to produce ATP at times of increased metabolic demand or decreased fuel supply. This mitochondrial plasticity is reduced in many age-associated diseases. In this review, we describe the serendipitous discovery of a novel class of compounds that selectively target cardiolipin on the inner mitochondrial membrane to optimize efficiency of the ETC and thereby restore cellular bioenergetics in aging and diverse disease models, without any effect on the normal healthy organism. The first of these compounds, SS-31, is currently in multiple clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available